256 related articles for article (PubMed ID: 36002185)
1. Antitumor efficacy of
Potluri HK; Ferreira CA; Grudzinski J; Massey C; Aluicio-Sarduy E; Engle JW; Kwon O; Marsh IR; Bednarz BP; Hernandez R; Weichert JP; McNeel DG
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36002185
[TBL] [Abstract][Full Text] [Related]
2. Myeloid-derived suppressor cells attenuate the antitumor efficacy of radiopharmaceutical therapy using
Muralidhar A; Hernandez R; Morris ZS; Comas Rojas H; Bio Idrissou M; Weichert JP; McNeel DG
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38663936
[TBL] [Abstract][Full Text] [Related]
3. Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade.
Patel RB; Hernandez R; Carlson P; Grudzinski J; Bates AM; Jagodinsky JC; Erbe A; Marsh IR; Arthur I; Aluicio-Sarduy E; Sriramaneni RN; Jin WJ; Massey C; Rakhmilevich AL; Vail D; Engle JW; Le T; Kim K; Bednarz B; Sondel PM; Weichert J; Morris ZS
Sci Transl Med; 2021 Jul; 13(602):. PubMed ID: 34261797
[TBL] [Abstract][Full Text] [Related]
4. Combined VLA-4-Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma.
Choi J; Beaino W; Fecek RJ; Fabian KPL; Laymon CM; Kurland BF; Storkus WJ; Anderson CJ
J Nucl Med; 2018 Dec; 59(12):1843-1849. PubMed ID: 29959213
[TBL] [Abstract][Full Text] [Related]
5. Temporal analysis of type 1 interferon activation in tumor cells following external beam radiotherapy or targeted radionuclide therapy.
Jagodinsky JC; Jin WJ; Bates AM; Hernandez R; Grudzinski JJ; Marsh IR; Chakravarty I; Arthur IS; Zangl LM; Brown RJ; Nystuen EJ; Emma SE; Kerr C; Carlson PM; Sriramaneni RN; Engle JW; Aluicio-Sarduy E; Barnhart TE; Le T; Kim K; Bednarz BP; Weichert JP; Patel RB; Morris ZS
Theranostics; 2021; 11(13):6120-6137. PubMed ID: 33995649
[No Abstract] [Full Text] [Related]
6. Integrin Ī±
Chen H; Zhao L; Fu K; Lin Q; Wen X; Jacobson O; Sun L; Wu H; Zhang X; Guo Z; Lin Q; Chen X
Theranostics; 2019; 9(25):7948-7960. PubMed ID: 31695808
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model.
Yu P; Steel JC; Zhang M; Morris JC; Waitz R; Fasso M; Allison JP; Waldmann TA
Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6187-92. PubMed ID: 22474386
[TBL] [Abstract][Full Text] [Related]
8. Radiation to all macroscopic sites of tumor permits greater systemic antitumor response to in situ vaccination.
Carlson PM; Patel RB; Birstler J; Rodriquez M; Sun C; Erbe AK; Bates AM; Marsh I; Grudzinski J; Hernandez R; Pieper AA; Feils AS; Rakhmilevich AL; Weichert JP; Bednarz BP; Sondel PM; Morris ZS
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36639155
[TBL] [Abstract][Full Text] [Related]
9. Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model.
Philippou Y; Sjoberg HT; Murphy E; Alyacoubi S; Jones KI; Gordon-Weeks AN; Phyu S; Parkes EE; Gillies McKenna W; Lamb AD; Gileadi U; Cerundolo V; Scheiblin DA; Lockett SJ; Wink DA; Mills IG; Hamdy FC; Muschel RJ; Bryant RJ
Br J Cancer; 2020 Sep; 123(7):1089-1100. PubMed ID: 32641865
[TBL] [Abstract][Full Text] [Related]
10. Low-Dose Radiation Potentiates the Propagation of Anti-Tumor Immunity against Melanoma Tumor in the Brain after In Situ Vaccination at a Tumor outside the Brain.
Clark PA; Sriramaneni RN; Bates AM; Jin WJ; Jagodinsky JC; Hernandez R; Le T; Jeffery JJ; Marsh IR; Grudzinski JJ; Aluicio-Sarduy E; Barnhart TE; Anderson BR; Chakravarty I; Arthur IS; Kim K; Engle JW; Bednarz BP; Weichert JP; Morris ZS
Radiat Res; 2021 Jun; 195(6):522-540. PubMed ID: 33826741
[TBL] [Abstract][Full Text] [Related]
11. TNFR2 blockade alone or in combination with PD-1 blockade shows therapeutic efficacy in murine cancer models.
Case K; Tran L; Yang M; Zheng H; Kuhtreiber WM; Faustman DL
J Leukoc Biol; 2020 Jun; 107(6):981-991. PubMed ID: 32449229
[TBL] [Abstract][Full Text] [Related]
12. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the ResponseĀ of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
13. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.
Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J
Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878
[TBL] [Abstract][Full Text] [Related]
14. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
[TBL] [Abstract][Full Text] [Related]
15. PET imaging facilitates antibody screening for synergistic radioimmunotherapy with a
Ren J; Xu M; Chen J; Ding J; Wang P; Huo L; Li F; Liu Z
Theranostics; 2021; 11(1):304-315. PubMed ID: 33391476
[No Abstract] [Full Text] [Related]
16. Fibroblast activation protein targeted radiotherapy induces an immunogenic tumor microenvironment and enhances the efficacy of PD-1 immune checkpoint inhibition.
Zboralski D; Osterkamp F; Christensen E; Bredenbeck A; Schumann A; Hoehne A; Schneider E; Paschke M; Ungewiss J; Haase C; Robillard L; Simmons AD; Harding TC; Nguyen M
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2621-2635. PubMed ID: 37086273
[TBL] [Abstract][Full Text] [Related]
17. Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal.
Isoyama S; Mori S; Sugiyama D; Kojima Y; Tada Y; Shitara K; Hinohara K; Dan S; Nishikawa H
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34446575
[TBL] [Abstract][Full Text] [Related]
18. Combining toll-like receptor agonists with immune checkpoint blockade affects antitumor vaccine efficacy.
Jeon D; Hill E; Moseman JE; McNeel DG
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38702146
[TBL] [Abstract][Full Text] [Related]
19. B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade.
Singh S; Roszik J; Saini N; Singh VK; Bavisi K; Wang Z; Vien LT; Yang Z; Kundu S; Davis RE; Bover L; Diab A; Neelapu SS; Overwijk WW; Rai K; Singh M
Front Immunol; 2022; 13():794684. PubMed ID: 35720386
[TBL] [Abstract][Full Text] [Related]
20. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
